Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Find Wonderful Stream Voyage Objections On the planet - 25 Destinations Where Airfare Is Dropping The Most For Spring 2026, Per Dollar Flight Club Analysis
- 3From Squid Game to Your Party! Six Entertaining Test Games That Will Have You in Join
- 4Boats escort freed whale away from shallow waters off German coast
- 5Figure out How to Function Successfully with Your Auto Collision Legal advisor for the Best Result
- 6 Well known Ladies' Fragrances On the planet
- Noctourism: the new safari travel trend that's changing the wildlife we can photograph in Africa
- Visual communication Programming for Fledglings
- Germany's Bundestag extends two armed forces missions abroad
- A Pompeii site reveals the recipe for Roman concrete. It contradicts a famous architect’s writings
- Trump awarded 1st FIFA Peace Prize by Gianni Infantino at 2026 World Cup draw
- $30K Disability Scam Implodes After Surf Trip in Mexico
- Find the Effect of Web-based Entertainment on Society: Exploring the Computerized Scene
- Figure out How to Augment Eco-friendliness in Your Volvo XC40
